October 19th, 2009 - Amine Abina, President and Chief Executive Officer of Nokad, announced that NOKAD has closed a second round of financing for 1.6 million euros from new venture capital shareholder, SHAM, and existing venture capital shareholders, CapDecisif Management and G1J Ile-de-France. The raised funds will help NOKAD to prepare its first clinical trial for the treatment of congenital thrombocytopenia, and continue the expansion of its in vivo target validation platform... NOKAD's Press Releases - PDF du communiqué de presse NOKAD-Nokad : COMPANY PROFILE
Nokad is a biotech start up created in January 2004 by three experienced scientists with scientific medical, pharmaceutical and business skills. The head office and the laboratory are located at Genopole® d'Evry ( France ). Nokad developed a new technology that allows the inactivation of secreted proteins in vivo in 6 months, whatever the species required.Nokad was selected for pertinence and high potential for success by the Aventis-Institut de France Foundation in 2003 (Tremplins 2003). Nokad is supported by Genopole Entreprises.
Recent Highlights Anticipated Highlights 8 secreted targets efficiently neutralized by the protein-function-KO technology, with Rat and mice protein-Knock-Out successfully obtained. Two new patents filled in 2006 and 2007, in thrombocytopenia treatment and in a Erythropoietin-mice and -rat model. Validation of a vaccination strategy for hypertriglyceridemia in 2009... About Nokad -
